Prevention of antiblastic neutropenia with lithium carbonate.
D000380:Agranulocytosis / Q000517:prevention & control*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008094:Lithium / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy; D009503:Neutropenia / Q000139:chemically induced / Q000517:prevention & control*; D009504:Neutrophils / Q000187:drug effects
D000970:Antineoplastic Agents; D008094:Lithium